Ray Dalio's Strategic Moves: SPDR S&P 500 ETF Trust Sees Significant Reduction
Ray Dalio (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, providing insights into his investment moves during this period. Ray Dalio (Trades, Portfolio) is the Founder, Co-Chairman, and Co-Chief Investment Officer of Bridgewater Associates. The guru started Bridgewater out of his two-bedroom apartment in New York in 1975. Under his leadership, the firm has grown into the fifth most important private company in the US according to Fortune Magazine. For his and Bridgewater's industry-changing innovations as well as his work advising policymakers around the world, Ray has been called the Steve Jobs of Investing by aiCIO Magazine and Wired Magazine, and named one of the 100 Most Influential People by TIME Magazine.Dalio is also the author of The New York Times #1 Bestseller "Principles," which outlines his work and life principles, the foundation of Bridgewater's distinctive culture and the cornerstone of his and Bridgewaters success. Ray and Bridgewater also recently published "Principles for Navigating Big Debt Crises," the first public dissemination of their research on these economic events, which enabled them to anticipate the 2008 Financial Crisis. Dalio built Bridgewater using a principled-based approach, applying standard ways to deal with situations that occur over and over. With the goal of creating an idea meritocracy, he wrote a set of principles that became the framework for the firm's management philosophy. Chief among them is employing radical truth and radical transparency encouraging open and honest dialogue and allowing the best thinking to prevail. His principles were captured in a TED Talk and published in a bestselling book in 2017.As a global macro-investment manager, Bridgewater takes a diversified approach spanning more than 150 different markets. With deep expertise in portfolio construction and risk management, the firm develops insights and design strategies to deliver value to its clients through any economic environment.
Ray Dalio (Trades, Portfolio) added a total of 123 stocks, among them:
The most significant addition was SPDR Gold Shares ETF (GLD), with 1,106,395 shares, accounting for 1.48% of the portfolio and a total value of $318.8 million.
The second largest addition to the portfolio was JD.com Inc (NASDAQ:JD), consisting of 2,786,833 shares, representing approximately 0.53% of the portfolio, with a total value of $114.6 million.
The third largest addition was United Airlines Holdings Inc (NASDAQ:UAL), with 1,531,302 shares, accounting for 0.49% of the portfolio and a total value of $105.7 million.
Ray Dalio (Trades, Portfolio) also increased stakes in a total of 283 stocks, among them:
The most notable increase was Alibaba Group Holding Ltd (NYSE:BABA), with an additional 5,405,235 shares, bringing the total to 5,660,258 shares. This adjustment represents a significant 2,119.51% increase in share count, a 3.31% impact on the current portfolio, with a total value of $748.5 million.
The second largest increase was Baidu Inc (NASDAQ:BIDU), with an additional 1,879,715 shares, bringing the total to 2,076,305. This adjustment represents a significant 956.16% increase in share count, with a total value of $191.1 million.
Ray Dalio (Trades, Portfolio) completely exited 150 of the holdings in the first quarter of 2025, as detailed below:
ON Semiconductor Corp (NASDAQ:ON): Ray Dalio (Trades, Portfolio) sold all 676,720 shares, resulting in a -0.2% impact on the portfolio.
Moderna Inc (NASDAQ:MRNA): Ray Dalio (Trades, Portfolio) liquidated all 605,782 shares, causing a -0.12% impact on the portfolio.
Ray Dalio (Trades, Portfolio) also reduced positions in 252 stocks. The most significant changes include:
Reduced SPDR S&P 500 ETF Trust (SPY) by 4,889,807 shares, resulting in a -59.4% decrease in shares and a -13.14% impact on the portfolio. The stock traded at an average price of $587.78 during the quarter and has returned -3.37% over the past 3 months and 0.52% year-to-date.
Reduced AppLovin Corp (NASDAQ:APP) by 486,443 shares, resulting in a -98.7% reduction in shares and a -0.72% impact on the portfolio. The stock traded at an average price of $344.61 during the quarter and has returned -26.61% over the past 3 months and 15.62% year-to-date.
At the first quarter of 2025, Ray Dalio (Trades, Portfolio)'s portfolio included 664 stocks, with top holdings including 8.67% in SPDR S&P 500 ETF Trust (SPY), 5.67% in iShares Core S&P 500 ETF (IVV), 4.75% in iShares Core MSCI Emerging Markets ETF (IEMG), 3.47% in Alibaba Group Holding Ltd (NYSE:BABA), and 2.18% in Alphabet Inc (NASDAQ:GOOGL).
The holdings are mainly concentrated in all 11 industries: Technology, Financial Services, Consumer Cyclical, Communication Services, Healthcare, Industrials, Energy, Consumer Defensive, Utilities, Basic Materials, and Real Estate.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
3 hours ago
- Business Insider
China Liberal Education announces suspension of Nasdaq trading
China Liberal Education (CLEU) announced that on May 30, 2025, the Company received notice from The Nasdaq Stock Market LLC that the Company's securities will be suspended from trading on Nasdaq effective June 3, 2025. The suspension is due to the Company's failure to submit a request for an extended stay or otherwise address the delinquency in filing its annual report on Form 20-F for the fiscal year ended December 31, 2024, in its written submissions to the Nasdaq Hearings Panel. Confident Investing Starts Here:
Yahoo
4 hours ago
- Yahoo
Jim Cramer and Wall Street Are Watching DraftKings Inc. (DKNG)
We recently published a list of . In this article, we are going to take a look at where DraftKings Inc. (NASDAQ:DKNG) stands against other stocks on Jim Cramer and Wall Street's radar. During the May 2 episode, Cramer mentioned DraftKings Inc. (NASDAQ:DKNG) and said: 'Will DraftKings make a comeback here? We like this company very much, but the stock does seem stalled, doesn't it? Maybe it needs more states to legalize sports betting.' A woman at a betting table paying out customers who won their sports bets. DraftKings Inc. (NASDAQ:DKNG) is a digital gaming company that focuses on online sports betting, daily fantasy sports, online casino games, and a digital collectibles marketplace. Additionally, the company develops software for sports betting and iGaming across both online and retail platforms. On May 30, Morgan Stanley analyst Stephen Grambling reduced the price target on DraftKings (NASDAQ:DKNG) from 53 to $51 while maintaining an Overweight rating. The firm slightly increased estimates for its Gaming & Lodging coverage due to stronger first-quarter results, expected guidance, and updated valuations based on higher multiples. The analyst noted that low valuations in the sector indicate the market remains cautious in the near term. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US." Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. About ASP Isotopes Inc. ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company has isotope enrichment facilities in Pretoria, South Africa. For more information, please visit About Isotopia Molecular Imaging Ltd. Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy. This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. Contact: eshalom@ SOURCE Isotopia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data